VA Western New York Health Care System, Buffalo, New York; Center for Research in Cardiovascular Medicine, University at Buffalo, Buffalo, New York; Department of Medicine, University at Buffalo, Buffalo, New York.
Center for Research in Cardiovascular Medicine, University at Buffalo, Buffalo, New York.
J Am Coll Cardiol. 2014 Jan 21;63(2):141-9. doi: 10.1016/j.jacc.2013.07.096. Epub 2013 Sep 25.
The PAREPET (Prediction of ARrhythmic Events with Positron Emission Tomography) study sought to test the hypothesis that quantifying inhomogeneity in myocardial sympathetic innervation could identify patients at highest risk for sudden cardiac arrest (SCA).
Left ventricular ejection fraction (LVEF) is the only parameter identifying patients at risk of SCA who benefit from an implantable cardiac defibrillator (ICD).
We prospectively enrolled 204 subjects with ischemic cardiomyopathy (LVEF ≤35%) eligible for primary prevention ICDs. Positron emission tomography (PET) was used to quantify myocardial sympathetic denervation ((11)C-meta-hydroxyephedrine [(11)C-HED]), perfusion ((13)N-ammonia) and viability (insulin-stimulated (18)F-2-deoxyglucose). The primary endpoint was SCA defined as arrhythmic death or ICD discharge for ventricular fibrillation or ventricular tachycardia >240 beats/min.
After 4.1 years follow-up, cause-specific SCA was 16.2%. Infarct volume (22 ± 7% vs. 19 ± 9% of left ventricle [LV]) and LVEF (24 ± 8% vs. 28 ± 9%) were not predictors of SCA. In contrast, patients developing SCA had greater amounts of sympathetic denervation (33 ± 10% vs. 26 ± 11% of LV; p = 0.001) reflecting viable, denervated myocardium. The lower tertiles of sympathetic denervation had SCA rates of 1.2%/year and 2.2%/year, whereas the highest tertile had a rate of 6.7%/year. Multivariate predictors of SCA were PET sympathetic denervation, left ventricular end-diastolic volume index, creatinine, and no angiotensin inhibition. With optimized cut-points, the absence of all 4 risk factors identified low risk (44% of cohort; SCA <1%/year); whereas ≥2 factors identified high risk (20% of cohort; SCA ∼12%/year).
In ischemic cardiomyopathy, sympathetic denervation assessed using (11)C-HED PET predicts cause-specific mortality from SCA independently of LVEF and infarct volume. This may provide an improved approach for the identification of patients most likely to benefit from an ICD. (Prediction of ARrhythmic Events With Positron Emission Tomography [PAREPET]; NCT01400334).
PAREPET(正电子发射断层扫描预测心律失常事件)研究旨在检验以下假设,即定量评估心肌交感神经支配的不均一性可以识别发生心源性猝死(SCA)风险最高的患者。
左心室射血分数(LVEF)是唯一可识别有 SCA 风险且受益于植入式心脏除颤器(ICD)的参数。
我们前瞻性纳入 204 名符合原发性 ICD 适应证的缺血性心肌病患者(LVEF≤35%)。正电子发射断层扫描(PET)用于定量评估心肌去交感神经支配(11C-间羟麻黄碱[(11)C-HED])、灌注(13N-氨)和存活(胰岛素刺激的18F-2-脱氧葡萄糖)。主要终点为心律失常性死亡或 ICD 放电导致室颤或室性心动过速>240 次/分定义的 SCA。
随访 4.1 年后,SCA 的特定病因发生率为 16.2%。梗死容积(22±7%比 19±9%的左心室[LV])和 LVEF(24±8%比 28±9%)不是 SCA 的预测因素。相反,发生 SCA 的患者有更多的去交感神经支配(33±10%比 26±11%的 LV;p=0.001),反映了存活但去神经支配的心肌。去交感神经支配的下三分位数的 SCA 发生率为 1.2%/年和 2.2%/年,而最高三分位数的 SCA 发生率为 6.7%/年。SCA 的多变量预测因素为 PET 去交感神经支配、左心室舒张末期容积指数、肌酐和无血管紧张素抑制。采用优化切点,4 个风险因素均不存在时,风险较低(44%的队列;SCA<1%/年);而≥2 个因素存在时,风险较高(20%的队列;SCA~12%/年)。
在缺血性心肌病中,使用11C-HED PET 评估去交感神经支配可独立于 LVEF 和梗死容积预测由 SCA 引起的特定原因死亡率。这可能为识别最有可能受益于 ICD 的患者提供一种改进的方法。(正电子发射断层扫描预测心律失常事件[PAREPET];NCT01400334)。